Navigation Links
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial

nd a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin has also been shown to be effective in animal studies for the prophylactic treatment of inhalation anthrax post exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the FDA has not yet approved the drug for marketing in this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationshi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
2. Cethromycin Shown Effective Against Anthrax in Study
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
7. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
8. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
9. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
Post Your Comments:
(Date:4/27/2015)... , April 27, 2015   AMC Health , ... showcase advances in monitored care that are transforming chronic ... ATA 2015 Conference, May 2-5 at the ... Health will share information about how their innovative ... help transform and personalize healthcare delivery at Booth #2116 ...
(Date:4/27/2015)... NEW YORK , April 27, 2015 ... claims against the board of directors of Aerie Pharmaceuticals, ... concerning whether the board has breached its fiduciary duties ... Company issued a press release announcing results from its ... things, the press release disclosed that in the trial, ...
(Date:4/27/2015)... 2015  USL di Reggio Emilia, the Regional Health ... has implemented Zebra Technologies Corporation (NASDAQ: ... Wireless Network Solution (WNS) provided by Zebra has ... in real time via mobile computers, contributing to improved ... also provides employee and guest Wi-Fi access and enables ...
Breaking Medicine Technology:AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... NEW YORK, Nov. 9 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... pharmaceutical,company dedicated to improving health through the development, manufacture ... the counter ("OTC"),products, today announced that it plans to ... 2009, after the market closes. , ...
... 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today ... , Arena reported a lower net loss allocable to common stockholders ... per share, compared to a net loss allocable to common stockholders ... per share, and a net loss allocable to common stockholders in ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
(Date:4/27/2015)... 2015 According to a recent report ... after chronic back pain, TMJ disorders are the ... and disability. In addition, the report revealed that TMJ ... population, costing an estimated 4 billion dollars annually. , ... from seemingly unrelated symptoms such as headaches, neck pain, ...
(Date:4/27/2015)... 2015 The Doctors on Liens ... of personal injury attorneys with the best doctors working on ... steady growth throughout their history and that trend continues with ... and his team in the Tujunga / Sunland ... massage therapist, patients can find comprehensive care and detailed documentation ...
(Date:4/27/2015)... NJ (PRWEB) April 27, 2015 ... firm, is proud to announce their sponsorship of ... Warren Counties. Girls on the Run is ... third through eighth grade. The program is delivered ... with uplifting workouts aimed to develop the whole ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is ... at the Alpine Valley Music Theatre and the Isleta ... and Albuquerque, New Mexico area can celebrate because their ... the woods. Buffett will be performing alongside legendary ... His tour stops during the summer and fall months ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:TayganPoint Consulting Group Announces Sponsorship of Girls on the Run 2Health News:Cheap Jimmy Buffett Tickets at Alpine Valley Music Theatre in Elkhorn, WI and at Isleta Amphitheater in Albuquerque, NM Now on Sale at TicketDown.com 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... ... contacted the Metropolitan Washington, DC Chapter of the Cystic Fibrosis (CF) Foundation 12 ... Melissa and 3-year old son Matthew had recently been diagnosed with the genetic ... age of survival for a child with CF was about 20 years. ...
... ... falling apart at home, psychotherapeutic interventions provide families with a growing array of options. ... (PRWEB) February 25, 2010 -- ... apart at home, psychotherapeutic interventions provide families with a growing array of options., , ,There ...
... ... braking system, affects millions of drivers , ... New York, NY (Lexis Nexis) February 25, 2010 -- The ... led to a significant increase in inquiries from individuals who are concerned about the ...
... A new study found that fluoxetine (Prozac) and ... collagen-induced arthritis (CIA) in mice. Research led ... Sussex Medical School (BSMS) in the UK studied ... selective serotonin reuptake inhibitors (SSRIs), most commonly used ...
... Special Issue of Business Horizons ( www.elsevier.com/locate/bushor ... Indiana University, and published by Elsevier, addresses issues central ... has been at the center of U.S. political debate ... support from Congress for passage of a national system ...
... ... ... ... ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Toyota Recalls Raise Awareness of Vehicle Safety Issues, Risks of Accidents from Driving Defective Automobiles 2Health News:Prozac and Celexa exhibit anti-inflammatory effects 2Health News:New Business Horizons special issue on US health care 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 2Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 3Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 4Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 5Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 6Health News:The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies' Failure to Provide Adequate Safety Research 7
... offers a range of standard, enhanced ... delivers therapy to meet the needs ... in commercial and clinical effectiveness and ... the SleepStyle 200 series is the ...
... The ResMed S6 Lightweight II CPAP ... microprocessor-controlled motor that maintains consistent pressure. ... and adjusting the settings easy, and ... and make adjustments is simple. This ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
Medicine Products: